MaxCyte to Report First Quarter 2023 Financial Results on May 10, 2023
12 avr. 2023 16h05 HE
|
MaxCyte, Inc
ROCKVILLE, Md., April 12, 2023 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the...
MaxCyte Appoints Douglas Swirsky as Chief Financial Officer
27 mars 2023 16h05 HE
|
MaxCyte, Inc
ROCKVILLE, Md., March 27, 2023 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (Nasdaq: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the...
MaxCyte Reports Fourth Quarter and Full Year 2022 Financial Results
15 mars 2023 16h05 HE
|
MaxCyte, Inc
ROCKVILLE, Md., March 15, 2023 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the...
MaxCyte Establishes New Scientific Advisory Board Comprised of Globally Recognized Experts in Cell Engineering Enabling Technology
08 mars 2023 08h00 HE
|
MaxCyte, Inc
ROCKVILLE, Md., March 08, 2023 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (Nasdaq: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the...
MaxCyte Announces Preliminary Unaudited Fourth Quarter and Full Year 2022 Revenue Results and Provides 2023 Revenue Guidance
06 mars 2023 16h05 HE
|
MaxCyte, Inc
Full year 2022 total revenue expected to be approximately $44.3 million, representing growth of 31% over full year 2021Fourth quarter 2022 total revenue expected to be approximately $12.4 million,...
MaxCyte to Report Fourth Quarter and Full Year 2022 Financial Results on March 15, 2023 and Participate in Upcoming Investor Conferences
01 févr. 2023 16h05 HE
|
MaxCyte, Inc
ROCKVILLE, Md., Feb. 01, 2023 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the...
MaxCyte Signs Strategic Platform License with Catamaran Bio to Support its CAR-NK Cell Therapy Programs
03 janv. 2023 16h05 HE
|
MaxCyte, Inc
ROCKVILLE, Md., Jan. 03, 2023 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (Nasdaq: MXCT; LSE: MXCT), a leading commercial cell-engineering company providing enabling platform technologies to advance...
MaxCyte Signs Strategic Platform License with Curamys to Enable Cell & Gene Therapies for the Treatment of Rare Intractable Diseases
05 déc. 2022 02h00 HE
|
MaxCyte, Inc
ROCKVILLE, Md. and SEOUL, South Korea, Dec. 04, 2022 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform...
MaxCyte Reports Third Quarter 2022 Financial Results
09 nov. 2022 16h05 HE
|
MaxCyte, Inc
22% Year-Over-Year Core Business Revenue Growth in Third Quarter 2022 Reiterates 2022 Revenue Guidance ROCKVILLE, Md., Nov. 09, 2022 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT),...
MaxCyte to Participate in Upcoming Investor Conferences
02 nov. 2022 08h05 HE
|
MaxCyte, Inc
ROCKVILLE, Md., Nov. 02, 2022 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the...